Management of Insomnia and Generalized Anxiety Disorder

Non-Pharmacological Interventions

The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as a first-line treatment for insomnia, which demonstrates superior long-term efficacy compared to pharmacotherapy alone, with sustained benefits after discontinuation 1, 2
CBT-I includes stimulus control therapy, sleep restriction therapy, relaxation techniques, and cognitive restructuring, and should be initiated before or alongside any medication 1
Sleep hygiene education alone is insufficient as monotherapy but should supplement other CBT-I components 1

The American Academy of Sleep Medicine recommends sedating antidepressants as the preferred initial pharmacological choice for patients with comorbid insomnia and generalized anxiety disorder (GAD) because they simultaneously address both the mood/anxiety disorder and sleep disturbance 1
Low-dose doxepin 3-6 mg at bedtime is recommended for sleep maintenance insomnia, reducing wake after sleep onset by 22-23 minutes with minimal anticholinergic effects at this dose 1
Ramelteon 8 mg at bedtime is recommended for sleep onset insomnia, with zero addiction potential and no controlled substance scheduling 1, 3
Sertraline 50-200 mg daily or escitalopram 10-20 mg daily is recommended for GAD, and can be combined with sleep medications for dual diagnosis 1

Traditional benzodiazepines (lorazepam, clonazepam, diazepam) should be avoided entirely due to high dependence potential, severe withdrawal syndromes, cognitive impairment, and fall risk 1, 3
Trazodone is explicitly not recommended by the American Academy of Sleep Medicine for insomnia due to lack of efficacy data and cardiac risks 1, 3
Over-the-counter antihistamines (diphenhydramine) are not recommended due to lack of efficacy data, strong anticholinergic effects, daytime sedation, and tolerance development after 3-4 days 1, 3

Start CBT-I immediately alongside any pharmacotherapy, and begin SSRI (sertraline or escitalopram) for GAD at standard starting doses 1, 3
Add sleep medication based on insomnia pattern, with Ramelteon 8 mg for sleep onset and doxepin 3-6 mg for sleep maintenance 1
Reassess after 1-2 weeks to evaluate efficacy on sleep latency, sleep maintenance, and daytime functioning, and monitor for adverse effects including morning sedation, cognitive impairment, and complex sleep behaviors 1

Educate patients on treatment goals and realistic expectations, safety concerns and potential side effects, and the importance of behavioral interventions alongside medication 1, 2
Warn patients about complex sleep behaviors (sleep-driving, sleep-walking) and the importance of maintaining sleep logs to track improvement objectively 1, 3

Use the lowest effective dose for the shortest duration possible, and consider medication tapering facilitated by CBT-I 1, 2
Chronic medication may be indicated for severe or refractory cases, but requires consistent follow-up and ongoing assessment 2